Skip to main content

Table 4 miRNAs involved in therapeutic response (sensitivity/resistance) in BC

From: Decoding the usefulness of non-coding RNAs as breast cancer markers

Therapies

Role in response

miRNA

Putative targets

Agent

Biological samples

Refs.

Hormone therapy

Antiestrogens

Sensitivity

miR-342

CCNB1

Tamoxifen

Cell lines and tumor tissues

[149]

miR-26a

EZH2

 

Tumor tissues

[150]

miR-30c

EGFR

  

[147]

miR-10, -126

–

  

[151]

Resistance 

miR-221/222

CDKN1B

Tamoxifen, fulvestrant

Tumor tissues and cell lines

[152, 153]

miR-519a

CDKN1B PTEN, RB1

Tamoxifen

Tumor tissues and cell lines

[154]

miR-155

SOCS6

  

[131]

miR-210

–

 

Tumor tissues

[110]

miR-301

FOXF2, BBC3, PTEN, COL2A1

 

Tumor tissues, cell lines and xenografts

[94]

Aromatase inhibitors 

Sensitivity

miR-125b let-7c

ERBB2

Letrozole, anastrozole

Tumor tissues and cell lines

[116]

Resistance

miR-181a

BCL2L11

Letrozole

Cell lines, xenografts and tumor tissues

[155]

Antibodies 

Sensitivity

miR-210

–

Trastuzumab

Cell lines and plasma

[148]

Resistance

miR-21

PTEN

Trastuzumab

Cell lines, xenograft and tumor tissues

[156]

Chemotherapy

Sensitivity

miR-451

MRP-1

Doxorubicin

Cell lines and tumor tissues

[157]

miR-200c

MRP-1

  

[158]

miR-134

ABCC1

  

[159]

miR-128

BMI1, ABCC5

Doxorubicin, Paclitaxel

Cell lines, xenografts and tumor tissues

[121]

miR-100

MTOR

Paclitaxel

Cell lines, xenografts and luminal tumor tissues

[119]

miR-16

IKBKB

 

Cell lines and tumor tissues

[160]

miR-621

FBXO11

Paclitaxel + Carboplatin

Cell lines, xenografts and tumor tissues

[161]

Resistance

miR-125b

BAK1, E2F3

FEC

Cell lines, tumor tissues and serum

[162]

miR-141

−

Taxane, Anthracyclines

Cell lines and tumor tissues

[163]

miR-221

CDKN1B

 

Plasma

[164]

miR-155

FOXO3a

Paclitaxel, VP-16, Doxorubicin

Cell lines and tumor tissues

[165]

Radiotherapy

Sensitivity

miR-155

RAD51

–

Cell lines and TNBC tissues

[166]

  1. CCNB1 cyclin B1, EZH2 enhancer of zeste homolog 2, EGFR epidermal growth factor receptor, CDKN1B cyclin-dependent kinase inhibitor 1B, PTEN phosphatase and tensin homolog, RB1 retinoblastoma 1, SOCS6 suppressor of cytokine signaling 6, FOXF2 forkhead box F2, BBC3 BCL2 binding component 3, COL2A1 collagen type II alpha 1, ERBB2 Erb-B2 receptor tyrosine kinase 2, BCL2L11 Bcl-2-like protein 11, MRP1 multidrug resistance-associated protein 1, ABCC1 ATP binding cassette subfamily C member 1, BMI1 BMI1 polycomb ring finger oncogene, ABCC5 ATP binding cassette subfamily C member 5, MTOR mechanistic target of rapamycin, IKBKB IκB kinase β, FBXO11 F-box protein 11, BAK1 BCL2 antagonist/killer 1, E3F3 E2F transcription factor 3, FOXO3a Forkhead box O3a, RAD51 RAD51 recombinase, FEC 5-florouracil, epirubucin and cyclophosphamide